SNPXSynaptogenix, Inc.

Nasdaq synaptogen.com


$ 3.50 $ 0.00 (0 %)    

Wednesday, 04-Sep-2024 12:00:20 EDT
QQQ $ 455.25 $ 5.77 (1.29 %)
DIA $ 409.08 $ 4.58 (1.13 %)
SPY $ 546.60 $ 6.05 (1.12 %)
TLT $ 99.96 $ 0.43 (0.43 %)
GLD $ 231.58 $ 0.97 (0.42 %)
$ 3.45
$ 3.56 x 100
-- x --
-- - --
$ 3.27 - $ 11.48
9,285
na
4.53M
$ 1.68
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-14-2024 06-30-2024 10-Q
2 05-15-2024 03-31-2024 10-Q
3 04-01-2024 12-31-2023 10-K
4 11-14-2023 09-30-2023 10-Q
5 08-14-2023 06-30-2023 10-Q
6 05-15-2023 03-31-2023 10-Q
7 03-21-2023 12-31-2022 10-K
8 11-10-2022 09-30-2022 10-Q
9 08-05-2022 06-30-2022 10-Q
10 05-13-2022 03-31-2022 10-Q
11 03-29-2022 12-31-2021 10-K
12 11-12-2021 09-30-2021 10-Q
13 08-13-2021 06-30-2021 10-Q
14 05-14-2021 03-31-2021 10-Q
15 03-30-2021 12-31-2020 10-K
16 12-23-2020 09-30-2020 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 synaptogenix-announces-collaboration-with-lsu-health-new-orleans-for-pre-clinical-testing-of-pufa-analogs-for-spinal-cord-injury

New Patent Issued Covering Treatment Of Neurodegenerative Diseases; Studies To Compare Analogs With Bryostatin In SCI

 maxim-group-upgrades-synaptogenix-to-buy-announces-14-price-target

Maxim Group analyst Jason McCarthy upgrades Synaptogenix (NASDAQ:SNPX) from Hold to Buy and announces $14 price target.

 synaptogenix-has-been-granted-us-patent-number-12016837-titled-halogenated-esters-of-cyclopropanated-unsaturated-fatty-acids-for-use-in-the-treatment-of-neurodegenerative-diseases-including-alzheimers-disease

https://ppubs.uspto.gov/pubwebapp/external.html?q=(12016837).pn

 synaptogenix-regains-compliance-with-nasdaq-minimum-bid-price-requirement-for-continued-listing

Synaptogenix, Inc. (NASDAQ:SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company devel...

 synaptogenix-acquires-25-stake-in-cannasoul

According to its most recent 10-K filing as of December 31, 2023, Synaptogenix reported a cash balance of $28.7 million. Additi...

 whats-going-on-with-synaptogenix-snpx-stock

Synaptogenix shares are trading lower Thursday morning. The company announced a 1-for-25 reverse stock split.

 why-etsy-shares-are-trading-lower-by-around-8-here-are-other-stocks-moving-in-thursdays-mid-day-session

Shares of Etsy, Inc.

 why-nvidia-shares-are-trading-higher-by-around-14-here-are-20-stocks-moving-premarket

Shares of NVIDIA Corporation (NASDAQ: NVDA) rose sharply in today’s pre-market trading after the company reported better-than-...

 synaptogenix-has-received-a-notice-of-allowance-for-its-us-patent-application-17665033-titled-halogenated-esters-of-cyclopropanated-unsaturated-fatty-acids-for-use-in-the-treatment-of-neurodegenerative-diseases

https://patentcenter.uspto.gov/applications/17665033/ifw/docs 

 why-amd-shares-are-trading-lower-here-are-other-stocks-moving-in-wednesdays-mid-day-session

Shares of Advanced Micro Devices, Inc. (NASDAQ: AMD) shares declined 3.8% to $165.49 following fourth-quarter results. AMD rep...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION